How Brexit Changed Medical Device Regulations

Introduction

When the United Kingdom left the European Union, it also left the EU's medical device regulatory framework. Great Britain — England, Scotland and Wales — established its own regulatory system, built on the existing UK Medical Devices Regulations 2002 as amended post-Brexit, with the MHRA as the national regulator and UKCA marking replacing CE marking as the route to market. Northern Ireland took a different path under the Windsor Framework and continues to accept CE-marked devices.

This guide explains what Brexit changed for medical device regulation, what the current UK framework looks like, what UKCA marking requires, how Northern Ireland differs, and what buyers and suppliers in the UK and beyond need to know now.

Brexit and medical devices in three changes

Brexit made three fundamental changes to the regulatory position of medical devices in the UK.

• Under a separate regulatory framework, Great Britain now operates under the UK MDR 2002 with UKCA marking, separate from the EU MDR with CE marking. Devices for the UK market must comply with UK rules; devices for the EU must comply with EU rules.

• UKCA marking replaces CE marking for GB. UKCA is the UK Conformity Assessed mark that replaced CE marking for Great Britain. Manufacturers must carry out a UK conformity assessment and register with the MHRA before affixing it.

• Northern Ireland remains under EU rules under the Windsor Framework. Northern Ireland continues to accept CE-marked devices and is treated as part of the EU single market for medical devices. Separate considerations apply.

What changed and when

1. The UK Medical Devices Regulations 2002, originally implementing EU directives, were retained in UK law after Brexit and amended to create a standalone UK framework. The MHRA became the national regulatory authority.

2. UKCA marking was introduced for Great Britain. In the UK, the UKCA marking was established as the market access route for Great Britain, replacing CE marking over a phased transition period. The mark requires UK conformity assessment, MHRA registration, and, for higher-risk devices, UK Approved Body approval.

3. CE marking is accepted under transitional arrangements to avoid an immediate supply cliff; the UK allowed CE-marked devices to continue to be placed on the GB market. These arrangements have been extended several times and continue to apply, but with phased-out deadlines by device class.

4. UK Approved Bodies, designated bodies equivalent to EU notified bodies, were designated by the MHRA to conduct conformity assessment for higher-risk devices under UKCA. Manufacturers must engage a UK AB for Class IIa and above. The 

5. MHRA device register states that manufacturers and authorised representatives must register medical devices with the MHRA before placing them on the GB market, using the MHRA's online portal.

6. UK Responsible Person requirement: Non-UK manufacturers must appoint a UK Responsible Person — equivalent to the EU Authorised Representative — who is registered with the MHRA, whose details must appear on the device label and the Declaration of Conformity.

7. Under the Windsor Framework, Northern Ireland is treated as an EU member state for medical device purposes. CE-marked devices can be placed on the Northern Ireland market and must follow EU MDR rules. Devices can move from Northern Ireland to Great Britain if they were lawfully placed on the Northern Ireland market.

8. As part of its reform programme, it has been developing a new UK regulatory framework for medical devices that will eventually diverge more substantially from the EU MDR. The pace and direction of this reform continue to evolve.

CE marking versus UKCA marking

Understanding the key differences between CE and UKCA marking helps buyers and suppliers navigate the post-Brexit position.

A device sold in both the EU and Great Britain may need to comply with both EU MDR and UK MDR, hold both CE and UKCA marks, and have both an EU Authorised Representative and a UK Responsible Person. This doubles some regulatory costs and timelines for manufacturers.

Navigating post-Brexit device requirements?

We supply medical equipment to both the UK and EU markets and manage UKCA and CE compliance across our range. Tell us the device and where you need it — we will confirm the current compliance position.

No pressure, no obligation. → Talk to the team

Current transitional arrangements for CE marking in GB

The transitional arrangements allowing CE-marked devices to be sold in Great Britain have been complex and frequently updated.

• Check the current MHRA guidance, which the MHRA publishes, detailing which device classes can still use CE marking in GB and until when. Always check the current published position rather than relying on summaries that may be out of date.

• Transitional arrangements are class-specific. The timeline for accepting CE marking in GB varies by device class and by whether the device is currently under an EU-notified-body certificate valid on 31 December 2020.

• UKCA transition is in progress. Manufacturers placing devices on the GB market for the long term should be progressing UKCA marking regardless of current transitional extensions. The transition will be complete.

• IVDs follow a separate timeline; in vitro diagnostics follow a different post-Brexit regulatory pathway and transitional timeline. Check IVD-specific MHRA guidance.

The MHRA's published guidance on post-Brexit transitional arrangements is the authoritative source. Given the frequency of updates, always consult the MHRA website for the current position rather than secondary summaries.

What buyers and suppliers should do now

Practical steps to manage post-Brexit device compliance for the UK market.

1. Check the current status of each device, and confirm whether each device you buy or sell for the GB market is UKCA-marked, CE-accepted under current transitional arrangements, or requires action to achieve compliance.

2. Confirm UK Responsible Person appointment: Non-UK manufacturers supplying to GB must have a UK Responsible Person registered with the MHRA. Check that this is in place for all devices you source.

3. Register devices with the MHRA to confirm that all devices placed on the GB market are registered.   This is the manufacturer's obligation, but buyers should verify it.

4. Monitor MHRA guidance for updates, sign up for MHRA email updates, and check the MHRA guidance pages regularly. Post-Brexit transitional timelines and requirements have changed multiple times.

5. Confirm Northern Ireland position separately if you are buying for or supplying to Northern Ireland; the position is different — CE marking applies under the Windsor Framework. Manage this separately from the GB compliance position if you are a manufacturer or distributor planning to supply GB for the foreseeable future. Begin the UKCA marking process now rather than relying on transitional arrangements indefinitely.

Brexit created a dual compliance requirement for organisations selling in both the UK and the EU. The investment in understanding and managing both frameworks is significant, but non-compliance in either market carries regulatory, reputational and financial risk.

Common Brexit compliance mistakes

These are the most common errors when navigating post-Brexit medical device regulation.

• Assuming CE marking still covers GB, CE marking alone does not automatically authorise a device for sale in Great Britain under current arrangements for all device classes. Check the current MHRA transitional guidance for the specific device class.

• Missing the UK Responsible Person requirement,t non-UK manufacturers must have a UK RP registered with the MHRA. Devices without a UK RP on the label are non-compliant for the GB market.

• Treating Northern Ireland the same as GB, Northern Ireland follows the EU regulatory framework for medical devices under the Windsor Framework — CE marking applies. Managing Northern Ireland and GB separately is essential.

• Not registering with the MHR, an MHRA device registration is a separate requirement from UKCA marking. Both are required to place devices on the GB market legally.

• Not monitoring MHRA guidance, transitional arrangements, timelines and requirements have changed multiple times since Brexit. Relying on outdated information creates compliance risk. Monitor the MHRA website directly.

Post-Brexit device regulation by territory

Post-Brexit UK device regulation differs by territory — Great Britain and Northern Ireland follow different rules.

Brexit affects only the y UK and EU market access. For Gulf and South African markets, CE marking (and now UKCA marking) continues to be accepted as evidence of regulatory compliance in registration applications.

More from Business

• Buyers — source UKCA and CE-accepted medical equipment for the UK and EU markets with current compliance.

• Suppliers — list your UKCA-marked and CE-certified devices and reach UK and EU buyers through medigear.uk.

• Advertise — promote your products and services to a clinical audience.

• Business overview — explore everything MediGear offers healthcare organisations.

Disclaimer

This article is for general information only and does not constitute legal, regulatory, procurement or clinical advice. Post-Brexit regulatory requirements, UKCA transitional arrangements and MHRA guidance change frequently. Always verify the current position with the MHRA directly and consult a qualified UK regulatory affairs professional for advice specific to your device, organisation and market. medigear.uk accepts no liability for actions taken based on this content.